Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

Rituximab 24Cyclophosphamide 20fludarabine phosphate 16Mycophenolic Acid 13Filgrastim 12Cyclosporine 12Bortezomib 12Antilymphocyte Serum 11Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Lenalidomide 9fludarabine 8Radiotherapy 7Methotrexate 7Cord Blood Stem Cell Transplantation 7Melphalan 6Busulfan 6venetoclax 5Etoposide 5tanespimycin 4ibrutinib 4Polymerase Chain Reaction 4Methylprednisolone 4Granulocyte Colony-Stimulating Factor 4Flow Cytometry 4ublituximab 3thymoglobulin 3sargramostim 3carfilzomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Mantle-Cell × MLN 8237 × Clear all
NCT01812005 2018-06-06

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
14 enrolled 11 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡